ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
    on August 11, 2026 at 8:00 am

    Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott's Lingo biowearable with Google's expertise in artificial intelligence (AI) and consumer technology, the multi-year collaboration makes personalized metabolic insights more actionable, helping people take a more proactive approach to their health.

  • New approach to the development of non-opioid painkillers
    on August 10, 2026 at 8:00 am

    An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom which significantly reduced inflammation-induced pain in an animal model. Crucially, its effect takes hold immediately after subcutaneous injection, whereas previously known cone snail peptides must be administered directly into the cerebrospinal fluid.

  • More than half of U.S. adults now eligible for statins under new guidelines
    on August 7, 2026 at 8:00 am

    More than half of U.S. adults ages 30 to 79 - about 87.5 million people - are now recommended for statins to prevent cardiovascular disease under newly updated clinical guidelines, according to a study by University of Pittsburgh School of Medicine researchers published in JAMA. The new recommendations significantly change how doctors assess cardiovascular risk by looking beyond the next 10 years to a person’s risk over several decades.

  • Many countries overusing powerful antibiotics
    on August 6, 2026 at 8:00 am

    Many countries are using too many powerful and inappropriate antibiotics, fuelling antibiotic resistance concerns, while millions lack access to the specific drugs they need. That is according to a major international study of antibiotic use published in The Lancet Public Health. Research led by City St George's, University of London and University of Oxford developed the first global framework that estimates how many and which type of antibiotics each country needs to treat their infections.

  • GLP-1 diabetes drugs linked to increased risk of hair loss
    on August 5, 2026 at 8:00 am

    Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ. Although the absolute risk is low, awareness of this potential effect may help to inform shared treatment decisions, say the researchers.